|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.57 CNY | -2.12% |
|
-6.79% | +9.74% |
| 12-07 | Yiling Pharmaceutical's Qifang Bitong Tablets Placed in China's Insurance Drug List | MT |
| 11-28 | Yiling Pharmaceutical Withdraws Drug Registration Application for Chaihuang Lidan Capsules | MT |
Evolution of the Average Target: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Evolution of the Target Price: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Changes in Analyst Recommendations: Shijiazhuang Yiling Pharmaceutical Co., Ltd.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +3.38% | |||||
| +25.87% | |||||
| +56.26% | |||||
| - | - | - | |||
| - | - | - | |||
| +14.23% | |||||
| - | - | +23.35% | |||
| - | - | +39.29% | |||
| Average | +27.06% | |||||
| Weighted average by Cap. | +26.68% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Annual profits - Rate of surprise
- Stock Market
- Equities
- 002603 Stock
- Consensus Shijiazhuang Yiling Pharmaceutical Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition